Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Long-Term Debt Repayments (2023)

Pasithea Therapeutics (KTTA) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $133335.0 as the latest value for Q3 2023.

  • Quarterly Long-Term Debt Repayments changed N/A to $133335.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $392354.0 through Dec 2023, changed N/A year-over-year, with the annual reading at $392354.0 for FY2023, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $133335.0 in Q3 2023 for Pasithea Therapeutics, up from $130768.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $133335.0 in Q3 2023 to a low of $128251.0 in Q1 2023.